SWOG clinical trial number
S9832

Enhancing Well-Being During Breast Cancer Recurrence

Closed
Phase
Accrual
100%
Published
Abbreviated Title
Breast Recurrence
Activated
07/15/1998
Closed
11/15/2002
Participants
NCORP, Members, Medical Oncologists

Research committees

Breast Cancer

Eligibility Criteria Expand/Collapse

Pt must have rec'd definitive surgical tx for Stage I, II or IIIa breast ca, w/or w/out adj chemo, hormonal, and/or RT. Pts must have been informed of 1st recurrence w/in past 56 days. Pt must be female w/no current psychiatric dx. Pt must be able to read/understand English. Pt must have completed baseline packet of questionnaires w/in 7 days prior to registration.

CANCER CONTROL CREDIT: 0.7
TREATMENT CREDIT: 0.0

Publication Information Expand/Collapse

2014

Enhancing nurse contributions to SWOG clinical trials

L Hansen;C Moinpour;R Ermete Seminars in Nursing Oncology 30(1):26-31;

PMid: PMID24559777 | PMC number: PMC3961058

2007

Impact of a peer-delivered telephone intervention for women experiencing a breast cancer recurrence [PMID17513815]

CC Gotay;CM Moinpour;JM Unger;CS Jiang;D Coleman;S Martino;BJ Parker;JD Bearden;SR Dakhil;HM Gross;S Lippman;KS Albain Journal of Clinical Oncology, 25(15):2093-2099

2004

Enhancing well-being during breast cancer recurrence: preliminary findings from a phase III study

CC Gotay;CM Moinpour;CS Jiang;DP Ankerst;D Coleman;S Martino;B Taylor;J Bearden;S Dakhil;H Gross;DS Albain Breast Cancer Research and Treatment 88(Suppl 1):S140 (#3080)

2000

Behavioral science research in the cooperative group setting: the Southwest Oncology Group Experience

CC Gotay;CM Moinpour;S Moody-Thomas;ER Gritz;KS Albain;E DeAntoni;L Hansen;PA Ganz Journal of the National Cancer Institute 92(17):1381-1387

An intervention to enhance well-being in women experiencing a breast cancer recurrence.

C Gotay;C Moinpour;K Albain;S Martino;S Green;B Taylor;J Perotti;CA Coltman, Jr. The Department of Defense Breast Cancer Research Program 2:779

Other Clinical Trials

SWOG Clinical Trial Number
S2206

A Randomized trial of neoadjuvant durvalumab plus chemotherapy versus chemotherapy alone for Adults with MammaPrint Ultrahigh (MP2) hormone receptor (HR) positive /Human Epidermal Growth Factor receptor (HER2) negative stage II-III breast cancer
Research Committee(s)
Breast Cancer
Symptom Control and Quality of Life
Activated
10/30/2023
Accrual
9%
Open
Phase
SWOG Clinical Trial Number
S2212

TIL Adapted Neo adjuvant Chemotherapy Optimization in Triple negative breast cancer (SCARLET)
Research Committee(s)
Breast Cancer
Activated
07/21/2023
Accrual
16%
Open
Phase
SWOG Clinical Trial Number
CTSU/NRG-BR007

A Phase III Clinical Trial Evaluating De-escalation of Breast Radiation for Conservative Treatment of Stage I, Hormone Sensitive, HER2-Negative, Treatment of Stage I, Hormone Sensitive, HER2-Negative, Oncotype Recurrence Score </= 18 Breast Cancer
Research Committee(s)
Breast Cancer
Activated
06/07/2021
Open
Phase